RUNX1 and myelodysplastic syndrome: These include t(8;21) RUNX1-RUNX1T1 translocation in 15% of AML patients [5], t(12;21) ETV6-RUNX1 translocation in 25% of BCP-ALL patients [6], and t(3;21) RUNX1-MECOM in therapy-related MDS/AML patients [7].